Revvity (NYSE:RVTY - Get Free Report) released its quarterly earnings results on Friday. The company reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.05, RTT News reports. Revvity had a return on equity of 7.42% and a net margin of 9.34%. During the same period in the prior year, the business posted $1.25 EPS. Revvity updated its FY 2025 guidance to 4.900-5.000 EPS.
Shares of NYSE RVTY traded up $0.39 during mid-day trading on Friday, reaching $127.23. 528,813 shares of the company were exchanged, compared to its average volume of 872,222. The stock has a market capitalization of $15.48 billion, a P/E ratio of 61.58, a P/E/G ratio of 4.09 and a beta of 1.03. The company has a quick ratio of 2.97, a current ratio of 3.56 and a debt-to-equity ratio of 0.40. The company's 50-day simple moving average is $116.60 and its 200-day simple moving average is $118.60. Revvity has a twelve month low of $97.32 and a twelve month high of $129.50.
The firm also recently declared a quarterly dividend, which will be paid on Friday, May 9th. Investors of record on Friday, April 18th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.22%. The ex-dividend date of this dividend is Thursday, April 17th. Revvity's dividend payout ratio (DPR) is presently 13.53%.
In other Revvity news, insider Tajinder S. Vohra sold 5,492 shares of the company's stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $116.81, for a total value of $641,520.52. Following the transaction, the insider now directly owns 19,652 shares of the company's stock, valued at $2,295,550.12. This represents a 21.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.60% of the stock is owned by company insiders.
Several equities research analysts have commented on the company. Leerink Partners boosted their target price on Revvity from $130.00 to $135.00 and gave the company an "outperform" rating in a research note on Thursday, October 17th. TD Cowen lifted their price target on shares of Revvity from $141.00 to $144.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. Bank of America upgraded shares of Revvity from a "neutral" rating to a "buy" rating and set a $138.00 price objective for the company in a research note on Friday, December 13th. Robert W. Baird lifted their target price on Revvity from $136.00 to $138.00 and gave the company an "outperform" rating in a research report on Tuesday, November 5th. Finally, Barclays reduced their price target on Revvity from $140.00 to $135.00 and set an "overweight" rating for the company in a research report on Monday, November 25th. Five research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $132.00.
Get Our Latest Stock Report on RVTY
Revvity declared that its Board of Directors has authorized a stock buyback plan on Monday, November 4th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 6.5% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board of directors believes its shares are undervalued.
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Revvity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revvity wasn't on the list.
While Revvity currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.